INM · Insider Trading
InMed Pharmaceuticals Inc. Common Shares
Every open-market purchase and sale reported by INM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +2,174 | +$2.87K |
| 2026-10-15 | Daniel Schneeberger | 10%+ Owner | Buy | +19,138 | +$25.44K |
| 2026-10-08 | Daniel Schneeberger | 10%+ Owner | Buy | +21,806 | +$28.97K |
| 2026-10-05 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +85,840 | +$114.16K |
| 2026-09-16 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +182,202 | +$236.15K |
| 2026-07-17 | Daniel Schneeberger | 10%+ Owner | Buy | +2,000 | +$3.11K |
| 2026-07-16 | Vivo Opportunity Cayman, LLC | 10%+ Owner | Buy | +82,184 | +$127.39K |
| 2026-07-02 | Vivo Opportunity, LLC | 10%+ Owner | Buy | +26,204 | +$40.59K |
| 2026-06-10 | Vivo Opportunity Cayman Fund, L.P. | 10%+ Owner | Buy | +996,908 | +$1.57M |
| 2026-05-21 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +937,102 | +$1.44M |
| 2025-12-19 | Shane Aaron Johnson | Sr VP & General Manager | A | +8,500 deriv. | — |
| 2025-12-19 | Netta Jagpal | Chief Financial Officer | A | +18,000 deriv. | — |
| 2025-12-19 | Eric A Adams | President & CEO | A | +35,000 deriv. | — |
| 2025-12-19 | Michael Woudenberg | Chief Operating Officer | A | +18,000 deriv. | — |
| 2025-12-19 | Nicole Lemerond | Director | A | +1,750 deriv. | — |
| 2025-12-19 | Neil A Klompas | Director | A | +1,750 deriv. | — |
| 2025-12-19 | Andrew Hull | Director | A | +1,750 deriv. | — |
| 2025-12-19 | Eric C Hsu | Sr. VP, Pre-Clinical Res/Dev | A | +13,000 deriv. | — |
| 2025-12-19 | John Steven Bathery | Director | A | +1,750 deriv. | — |
| 2025-12-17 | Eric C Hsu | Sr. VP, Pre-Clinical Res/Dev | H | −70 deriv. | — |
| 2025-12-17 | Michael Woudenberg | Chief Operating Officer | H | −60 deriv. | — |
| 2025-12-17 | Eric A Adams | President & CEO | H | −250 deriv. | — |
| 2025-12-17 | Andrew Hull | Director | H | −14 deriv. | — |
| 2025-10-21 | Neil A Klompas | Director | A | +3,500 deriv. | — |
| 2025-02-03 | Andrew Hull | Director | H | −2 deriv. | — |
| 2024-12-23 | Janet P Grove | Director | A | +550 deriv. | — |
| 2024-12-23 | Shane Aaron Johnson | Sr VP & General Manager | A | +1,500 deriv. | — |
| 2024-12-23 | Eric C Hsu | Sr. VP, Pre-Clinical Res/Dev | A | +2,750 deriv. | — |
| 2024-12-23 | Nicole Lemerond | Director | A | +550 deriv. | — |
| 2024-12-23 | Andrew Hull | Director | A | +550 deriv. | — |
| 2024-12-23 | Bryan T Baldasare | Director | A | +550 deriv. | — |
| 2024-12-23 | Michael Woudenberg | Chief Operating Officer | A | +3,750 deriv. | — |
| 2024-12-23 | Netta Jagpal | Chief Financial Officer | A | +3,750 deriv. | — |
| 2024-12-23 | Eric A Adams | President & CEO | A | +6,250 deriv. | — |
| 2024-08-02 | Alexandra Diane Janet Mancini | — | Sell | −240 | −$42 |
| 2024-05-28 | Eric C Hsu | Sr. VP, Pre-Clinical Res/Dev | H | −545 deriv. | — |
| 2024-05-28 | Alexandra Diane Janet Mancini | Sr VP, Clinical Reg Affairs | H | −485 deriv. | — |
| 2024-05-28 | Michael Woudenberg | Chief Operating Officer | H | −394 deriv. | — |
| 2024-05-28 | Eric A Adams | President & CEO | H | −1,139 deriv. | — |
| 2024-03-05 | Alexandra Diane Janet Mancini | Sr VP, Clinical Reg Affairs | H | −121 deriv. | — |
| 2024-03-05 | Andrew Hull | Director | H | −42 deriv. | — |
| 2024-03-05 | Eric C Hsu | Sr. VP, Pre-Clinical Res/Dev | H | −309 deriv. | — |
| 2024-02-22 | Andrew Hull | Director | Buy | +37,500 | +$14.62K |
| 2024-02-21 | Eric A Adams | President & CEO | Buy | +41,600 | +$14.92K |
| 2023-12-26 | Nicole Lemerond | Director | A | +7,100 deriv. | — |
| 2023-12-26 | Eric C Hsu | Sr. VP, Pre-Clinical Res/Dev | A | +45,000 deriv. | — |
| 2023-12-26 | Jonathan Tegge | Interim CFO | A | +30,000 deriv. | — |
| 2023-12-26 | Alexandra Diane Janet Mancini | Sr VP, Clinical Reg Affairs | A | +45,000 deriv. | — |
| 2023-12-26 | Michael Woudenberg | Chief Operating Officer | A | +65,000 deriv. | — |
| 2023-12-26 | Janet P Grove | Director | A | +7,100 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 10%+ Owner | 955,494 | $1.52M |
| Daniel Schneeberger | 10%+ Owner | 954,509 | $1.52M |
| Vivo Opportunity Cayman, LLC | 10%+ Owner | 729,277 | $1.16M |
| Vivo Opportunity, LLC | 10%+ Owner | 724,395 | $1.15M |
| Vivo Opportunity Cayman Fund, L.P. | 10%+ Owner | 638,960 | $1.02M |
| Eric A Adams | President & CEO | 2,198 | $3.49K |
| Andrew Hull | Director | 1,913 | $3.04K |
| Shane Aaron Johnson | Sr VP & General Manager | 609 | $968 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.